TrialBlood advances2022

Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT.

Hannah Kinoshita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.